Finanzas de IRadimed Corp (IRMD)IRMDIRadimed Corp

IRADIMED CORPORATION (IRMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MRI Compatible Patient Vital Signs Monitoring Systems, accounting for 32.6% of total sales, equivalent to $6.67M. Other significant revenue streams include MRI Compatible IV Infusion Pump Systems and Disposables, services and other. Understanding this composition is critical for investors evaluating how IRMD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, IRADIMED CORPORATION maintains a gross margin of 76.26%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 33.63%, while the net margin is 26.88%. These profitability ratios, combined with a Return on Equity (ROE) of 23.42%, provide a clear picture of how effectively IRMD converts its operational activities into shareholder value.

In the context of the broader market, IRMD competes directly with industry leaders such as STAA and AORT. With a market capitalization of $1.12B, it holds a leading position in the sector. When comparing efficiency, IRMD's gross margin of 76.26% stands against STAA's 74.55% and AORT's 64.03%. Such benchmarking helps identify whether IRADIMED CORPORATION is trading at a premium or discount relative to its financial performance.

IRadimed has shown a gross margin of 74% in Q2 2026, down from 78% in the previous year, indicating rising costs. The company reported total revenue of $20.5 million in Q2 2026, reflecting a mere 0.5% year-over-year increase, which is concerning for growth prospects.